Advertisement

Neurotoxicity Research

, Volume 12, Issue 2, pp 113–124 | Cite as

Behavioural supersensitivity following neonatal 6-hydroxydopamine: Attenuation by MK-801

  • T. Archer
  • Anders Fredriksson
Article

Abstract

Male rat pups were administered 6-hydroxydopamine (6-OHDA, 75 μg, intracisternally, 30 min after desipramine, 25 mg/kg, s.c.) on Days 1 or 2 after birth, or were sham-operated (receiving vehicle). In four experiments, the acute effects of apomorphine, with or without pretreatment with MK-801 (0.03 mg/kg), upon motor activity in test chambers was measured. Acute treatment with apomorphine (0.1 mg/kg) increased locomotor, rearing and total activity markedly compared to both the acute saline administered 6-OHDA rats and the sham-operated rats administered saline. Acute MK-801 (0.03 mg/kg) co-administered shortly before (5 min) apomorphine (0.3 or 1.0 mg/kg) reduced markedly locomotion and total activity in 6-OHDA-treated and sham-operated rats. Rearing behaviour was increased in both the 6-OHDA groups of rats. Acute MK-801 increased activity in the 6-OHDA-treated rats, which was not observed in sham-operated rats. At the 0.3 and 1.0 mg/kg doses of apomorphine, neonatal 6-OHDA treament increased all three parameters of motor activity. Acute treatment with apomorphine (0.1 mg/kg) induced different effects on the motor activity of 6-OHDA-treated and sham-operated mice. In sham-operated rats apomorphine reduced motor activity during the 1st 30-min period but increased locomotion and total activity, but not rearing, during the 2nd and 3rd periods, whereas in 6-OHDA-treated rats, apomorphine increased locomotor, rearing and total activity markedly. Dopamine loss and serotonin elevation in the striatum and olfactory tubercle were confirmed. The present findings confirm the influence of non-competitive glutamate antagonists in attenuating the behavioural supersensitivity to dopamine antagonists.

Keywords

6-Hydroxydopamine MK-801 Neonatal Apomorphine Locomotion Rearing Total activity Supersensitivity Attenuation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Archer T and A Fredriksson (1992) Functional changes implicating dopaminergic systems following perinatal treatments.Dev. Pharmacol. Ther. 18, 201–222.PubMedGoogle Scholar
  2. Archer T, A Fredriksson, G Jonsson, T Lewander, AK Mohammed, SB Ross and U Söderberg (1986) Central noradrenergic depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat.Psychopharmacology 88, 141–146.PubMedCrossRefGoogle Scholar
  3. Archer T, W Danysz, A Fredriksson, G Jonsson, J Luthman, E Sundström and A Teiling (1988) Neonatal 6-hydroxydopamine-induced dopamine depletions: motor activity and performance in maze learning.Pharmacol. Biochem. Behav. 31, 357–364.PubMedCrossRefGoogle Scholar
  4. Archer T, RJ Beninger, TUC Järbe and LS Seiden (1990) Latent learning in a radial arm maze following neonatal dopamine depletions.Behav. Pharmacol. 1, 191–199.CrossRefGoogle Scholar
  5. Archer T, M Bassen, D Peters, J Luthman and A Fredriksson (1996) Dopaminergic-glutamatergic balance in the fore-brain: functional studies of movement disorders in rats and mice, In:Dopamine Disease States (Beninger RJ, T Palomo and T Archer, Eds.) (Madrid University Press: Madrid), pp. 117–154.Google Scholar
  6. Archer T, T Palomo and A Fredriksson (2002a) Functional deficits following neonatal dopamine depletion and isolation housing: circular water maze acquisition under pre-exposure conditions and motor activity.Neurotox. Res. 4, 503–522.PubMedCrossRefGoogle Scholar
  7. Archer T, T Palomo and A Fredriksson (2002b) Neonatal 6-hydroxydopamine-induced hypo/hyperactivity: blockade by dopamine reuptake inhibitors and effect of acute D-amphetamine.Neurotox. Res. 4(3), 247–266.PubMedCrossRefGoogle Scholar
  8. Archer T, T Palomo, R McArthur and A Fredriksson (2003) Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.Neurotox. Res. 5, 95–110.PubMedGoogle Scholar
  9. Björk L, LJ Cornfield, DI Nelson, SE Hillver and NE Andén (1991) Pharmacology of the novel 5-hydroxytryptamine-1A receptor antagonist (S)-5-flouro-8-hydroxy-2-(dipropyl-amino) tetralin: inhibition of (R)-8-hydroxy-2-(dipropyl-amino)tetralin-induced effects.J. Pharmacol. Exp. Ther. 258, 58–65.PubMedGoogle Scholar
  10. Breese GR and RA Mueller (1985) SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholeaminergic neurons.Eur. J. Pharmacol. 113, 109–114.PubMedCrossRefGoogle Scholar
  11. Breese GR, A Baumeister, TC Napier, GD Frye and RA Mueller (1985) Evidence that D-1 dopamine receptors contribute to the supersensitive behavioural responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.J. Pharmacol. Exp. Ther. 235, 287–295.PubMedGoogle Scholar
  12. Breese GR, RA Mueller, TC Napier and GE Duncan (1986) Neurobiology of D1 dopamine receptors after neonatal 6-OHDA treatment: relevance to Lesch-Nyhan disease.Adv. Exp. Med. Biol. 204, 197–215.PubMedGoogle Scholar
  13. Breese GR, HE Criswell, GE Duncan, SS Moy, KB Johnson, DF Wong and RA Mueller (1995) Model for reduced brain dopamine in Lesch-Nyhan syndrome and the mentally retarded: neurobiology of neonatal 6-hydroxydopamine lesioned rats.Ment. Retard. Dev. Disabil. Res. Rev. 1, 111–119.CrossRefGoogle Scholar
  14. Breese GR, DJ Knapp, HE Criswell, SS Moy, ST Papadeas and BL Blake (2005) The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles.Brain Res. Rev. 48, 57–73.PubMedCrossRefGoogle Scholar
  15. Buonamici M, C Caccia, M Carpentieri, M Pegrassi, AC Rossi and G Di Chiara (1986) D-1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions.Eur. J. Pharmacol. 126, 347–348.PubMedCrossRefGoogle Scholar
  16. Carlsson M and A Carlsson (1989a) The NMDA antagonist MK-801 causes marked locomotion stimulation in monoamine-depleted mice.J. Neural Transm. 75, 221–226.PubMedCrossRefGoogle Scholar
  17. Carlsson M and A Carlsson (1989b) Dramatic synergism between MK-801 and clonidine with regard to locomotor stimulatory effect in monoamine-depleted mice.J. Neural Transm. 77, 65–71.PubMedCrossRefGoogle Scholar
  18. Carlsson M and A Svensson (1990) Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems.Pharmacol. Biochem. Behav. 36, 45–50.PubMedCrossRefGoogle Scholar
  19. Carlsson M, A Svensson and A Carlsson (1991) Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.Naunyn-Schmiedebergs Arch. Pharmacol. 343, 568–573.PubMedGoogle Scholar
  20. Chase TN, F Bibbiani and JD Oh (2003) Striatal glutamatergic mechanisms and extrapyramidal movement disorders.Neurotox. Res. 5, 139–146.PubMedGoogle Scholar
  21. Concannon JT and MD Schechter (1981) Hyperactivity in developing rats: sex differences in 6-hydroxydopamine and amphetamine effects.Pharmacol. Biochem. Behav. 14, 5–10.PubMedCrossRefGoogle Scholar
  22. Creese I and SD Iversen (1973) Blockade of amphetamine-induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine.Brain Res. 55, 369–382.PubMedCrossRefGoogle Scholar
  23. Criswell HE, RA Mueller and GR Breese (1990) Long-term D-1-dopamine receptor sensitization in neonatal 6-hydroxydopamine-lesioned rats is blocked by an NMDA antagonist.Brain Res. 512, 284–290.PubMedCrossRefGoogle Scholar
  24. Criswell HE, KB Johnson, RA Mueller and GR Breese (1993) Evidence for involvement of brain dopamine and other mechanisms in the behavioural action of theN-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.J. Pharmacol. Exp. Ther. 265, 1001–1010.PubMedGoogle Scholar
  25. Eastgate SM, JJ Wright and JS Werry (1978) Behavioural effects of methylphenidate in 6-hydroxydopaminetreated neonatal rats.Psychopharmacology 58, 157–159.PubMedCrossRefGoogle Scholar
  26. Erinoff L, RC MacPhail, A Heller and LS Seiden (1979) Age dependent effects of 6-hydroxydopamine on locomotor activity in the rat.Brain Res. 164, 195–205.PubMedCrossRefGoogle Scholar
  27. Fuxe K, BB Fredholm, LF Agnati, SO Ögren, BJ Everitt, G Jonsson and JÅ Gustafsson (1978a) Interaction of ergot drugs with central monoamine systems: evidence for a high potential in the treatment of mental and neurological disorders.Pharmacology 16 (Suppl. 1), 99–134.PubMedCrossRefGoogle Scholar
  28. Fuxe K, BB Fredholm, SO Ögren, LF Agnati, T Hökfelt and JÅ Gustafsson (1978b) Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioural analysis.Fed. Proc. 37, 2181–2191.PubMedGoogle Scholar
  29. Karler R, LD Calder, IA Chaudhry and SA Turkanis (1989) Blockade of “reverse tolerance” to cocaine and amphetamine by MK-801.Life Sci. 45, 599–606.PubMedCrossRefGoogle Scholar
  30. Kirk RE (1995)Experimental Design: Procedures for the Behavioural Sciences (Brooks/Cole: Belmont, CA).Google Scholar
  31. Klockgether T, L Turski, T Honore, Z Zhang, DM Gash, R Kurlan and T Greenamyre (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoaminedepleted rats and MPTP-treated monkeys.Ann. Neurol. 30, 717–723.PubMedCrossRefGoogle Scholar
  32. Kostrzewa RM (1995) Dopamine receptor supersensitivity.Neurosci. Biobehav. Rev. 19, 1–17.PubMedCrossRefGoogle Scholar
  33. Kostrzewa RM (2003) Dopamine receptor supersensitivity: an outcome and index of neurotoxicity.Neurotox. Res. 5, 111–118.PubMedGoogle Scholar
  34. Kostrzewa RM and A Hamdi (1991) Potentiation of spiperone-induced oral activity in rats after neonatal 6-hydroxydopamine.Pharmacol. Biochem. Behav. 38, 215–218.PubMedCrossRefGoogle Scholar
  35. Kostrzewa RM, R Brus, KW Perry and RW Fuller (1993) Age dependence of a 6-hydroxydopamine lesion on SKF 38393- andm-chlorophenylpiperazine-induced oral activity responses of rats.Brain Res. Dev. Brain Res. 76, 87–93.PubMedCrossRefGoogle Scholar
  36. Kronthaler UP, M Bubser and WJ Schmidt (1994) Behavioural functions of the mesostriatal system as revealed by 6-OHDA lesions in the striatum of rats.Proc. 22nd Göttingen Neurobiol. Conf. P. 761.Google Scholar
  37. Lieberman A, T Miyamoto, A Battista and M Goldstein (1975) Studies on the antiparkinsonian efficacy of lergotrile.neurology 25, 459–462.PubMedGoogle Scholar
  38. Lieberman A, M Zolfaghari, D Boal, H Hassouri, B Vogel, A Battista, K Fuxe and M Goldstein (1976) The antiparkinsonian efficacy of bromocriptine.Neurology 26, 405–409.PubMedGoogle Scholar
  39. Lieberman A, M Goldstein, G Gopinathan and A Neophyrides (1987) D-1 and D-2 agonists in Parkinson’s disease.Can. J. Neurol. Sci. 14, 466–473.PubMedGoogle Scholar
  40. Liu Y, H Yu, N Mohell, G Nordvall, T Lewander and U Hacksell (1995) Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.J. Med. Chem. 38, 150–160.PubMedCrossRefGoogle Scholar
  41. Luthman J, B Bolioli, T Tsutsumi, A Verhofstad and G Jonsson (1987) Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat.Brain Res. Bull. 19, 269–274.PubMedCrossRefGoogle Scholar
  42. Luthman J, A Fredriksson, T Lewander, G Jonsson and T Archer (1989a) Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment.Psychopharmacology 99, 550–557.PubMedCrossRefGoogle Scholar
  43. Luthman J, A Fredriksson, E Sundström, G Jonsson and T Archer (1989b) Selective lesion of central dopamine or noradrenaline systems in the neonatal rat: motor behaviour and monoamine alterations at adult stage.Behav. Brain Res. 33, 267–277.PubMedCrossRefGoogle Scholar
  44. Luthman J, A Fredriksson, A Plaznik and T Archer (1991) Ketanserin and mianserin treatment reverses hyperactivity in neonatally dopamine lesioned rats.J. Psychopharmacol. 5, 418–425.CrossRefGoogle Scholar
  45. Luthman J, E Lindqvist and SO Ögren (1995) Hyperactivity in neonatally dopamine-lesioned rats depends on residual activity in mesolimbic dopamine neurons.Pharmacol. Biochem. Behav. 51, 159–163.PubMedCrossRefGoogle Scholar
  46. Luthman J, M Bassen, A Fredriksson and T Archer (1997) Functional changes induced by 6-hydroxydopamine lesions: effects of dose levels on behavioural parameters.Behav. Brain Res. 82, 213–221.PubMedCrossRefGoogle Scholar
  47. Miller FE, TG Heffner, C Kotake and LS Seiden (1981) Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to brain dopamine depletion.Brain Res. 229, 123–132.PubMedCrossRefGoogle Scholar
  48. Morelli M and G Di Chiara (1990) MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson’s disease.Eur. J. Pharmacol. 182, 611–612.PubMedCrossRefGoogle Scholar
  49. Morelli M, S Fenu, A Pinna and G Di Chiara (1992) Opposite effects of NMDA receptor blockade on dopaminergic D1-and D2-mediated behaviour in 6-hydroxydopamine model of turning: relationship with c-fos expression.J. Pharmacol. Exp. Ther. 260, 402–408.PubMedGoogle Scholar
  50. Moy SS and GR Breese (2002) Phencyclidine supersensitivity in rats with neonatal dopamine loss.Psychopharmacology 161, 255–262.PubMedCrossRefGoogle Scholar
  51. Moy SS, HE Criswell and GR Breese (1997) Differential effects of bilateral dopamine depletion in neonatal and adult rats.Neurosci. Biobehav. Rev. 21, 425–435.PubMedCrossRefGoogle Scholar
  52. Ohno M, H Yoshida and S Watanabe (1994) NMDA receptor-mediation expression of Fos protein in the rat striatum following methamphetamine administration: relation to behavioural sensitization.Brain Res. 665, 135–140.PubMedCrossRefGoogle Scholar
  53. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (2006) Co-morbidity implications in brain disease: neuronal substrates of symptom profiles.Neurotox. Res. 10, 1–13.CrossRefGoogle Scholar
  54. Porter RHP and JT Greenemyre (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutics potential.J. Neurochem. 64, 614–623.PubMedCrossRefGoogle Scholar
  55. Roehrich H, CA Dackis and MS Gold (1987) Bromocriptine.Med. Res. Rev. 7, 243–269.PubMedCrossRefGoogle Scholar
  56. Rosenzweig-Lipson S, P Hesterberg and J Bergman (1994) Observational studies of dopamine D1 and D2 agonists in squirrel monkeys.Psychopharmacology 116, 9–18.PubMedCrossRefGoogle Scholar
  57. Schechter MD and NL Greer (1987) Evidence that the stimulus properties of apomorphine are mediated by both D1 and D2 receptor activation.Life Sci. 40, 2461–2471.PubMedCrossRefGoogle Scholar
  58. Shaywitz BA, HH Klopper, RD Yager and JW Gordon (1976) Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine.Nature 261, 153–155.PubMedCrossRefGoogle Scholar
  59. Sorensen CA, JS Vayer and CS Goldberg (1977) Amphetamine reduction of motor activity in rats after neonatal administration of 6-hydroxydopamine.Biol. Psychiatry 12, 133–137.Google Scholar
  60. Svensson A and M Carlsson (1991) Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation.Neuropharmacology 31, 513–518.CrossRefGoogle Scholar
  61. Wolf ME (1998) The role of excitatory amino acids in behavioural sensitization to psychomotor stimulants.Prog. Neurobiol. 54, 679–720.PubMedCrossRefGoogle Scholar
  62. Wolf ME and M Jeziorski (1993) Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioural sensitization.Brain Res. 613, 291–294.PubMedCrossRefGoogle Scholar
  63. Zhang K, FI Tarazi and RJ Baldessarini (2001) Role of dopamine(4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions.Neuropsychopharm-acology 25, 624–632.CrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  1. 1.Department of PsychologyUniversity of GöteborgGöteborgSweden
  2. 2.Department of Health and Behavioural ScienceKalmar UniversityKalmarSweden
  3. 3.Department of Neuroscience & PsychiatryUniversity of UppsalaUppsalaSweden

Personalised recommendations